ACRV - Acrivon Therapeutics, Inc.

1.66
0.060   3.614%

Share volume: 520,286
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$1.60
0.06
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
7.10%
1 Month
10.67%
3 Months
-36.40%
6 Months
7.10%
1 Year
-69.54%
2 Year
-66.46%
Key data
Stock price
$1.66
P/E Ratio 
0.00
DAY RANGE
$1.61 - $1.70
EPS 
-$2.11
52 WEEK RANGE
$1.05 - $5.65
52 WEEK CHANGE
-$68.86
MARKET CAP 
37.802 M
YIELD 
N/A
SHARES OUTSTANDING 
31.555 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.94
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$995,247
AVERAGE 30 VOLUME 
$986,340
Company detail
CEO: Peter Blume-Jensen
Region: US
Website: acrivon.com
Employees: 0
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. We were incorporated under the laws of the State of Delaware in March 2018. Our principal executive offices are located at 480 Arsenal Way, Suite 100, Watertown, Massachusetts.

Recent news